Story perspectives

Genomics Unveils AI Platform to Revolutionize Precision Medicine

10/21/2025

Summary

Story summary

Genomics launched Mystra, an AI-enabled human genetics platform, at the ASHG 2025 meeting in Boston, to accelerate drug target discovery and clinical validation amid an R&D crisis with trial failure rates approaching 90%.
GeneDx received Breakthrough Device Designation from the FDA for its whole genome and exome tests to identify genetic causes of serious diseases.
These advances in precision medicine emphasize personalized treatment and rapid diagnostics, moving toward proactive healthcare.

History

Historical Context

The Human Genome Project, initiated in 1990 and completed in 2003, mapped over 20,000 human genes at a cost of approximately $3 billion. This groundbreaking effort, led by the National Institutes of Health and the Department of Energy, has paved the way for advancements in precision medicine, including the launch of Genomics' Mystra platform, which aims to reduce the high trial failure rates in drug development.

1 of 2

Story summary

Genomics launched Mystra, an AI-enabled human genetics platform, at the ASHG 2025 meeting in Boston, to accelerate drug target discovery and clinical validation amid an R&D crisis with trial failure rates approaching 90%.
GeneDx received Breakthrough Device Designation from the FDA for its whole genome and exome tests to identify genetic causes of serious diseases.
These advances in precision medicine emphasize personalized treatment and rapid diagnostics, moving toward proactive healthcare.

1 / 2